The Street is missing the simplest tell in the document. Moderna's FY2025 10-K, filed February 20, 2026, reports research and development expense of about $3.1 billion for 2025 — the second straight annual decline from a $4.8 billion peak in 2023. Companies that believe their near-term revenue is about to inflect upward do not cut R&D two years running.
Read the cash line next. The same filing shows year-end cash and cash equivalents of about $2.6 billion, up from roughly $1.9 billion a year earlier. That improvement is not a growth signal — it is the signature of a company husbanding capital: spending less, conserving more, buying itself time to let the pipeline mature.
Acknowledge the bull case before dismantling it. The mRNA platform is genuinely a platform — the same machinery that produced a COVID vaccine can, in principle, address respiratory combinations, latent viruses, and oncology. Moderna's historical filings show the revenue ramp that platform once produced, with full-year revenue of about $18.5 billion in 2021. The optionality is real.
But optionality is not revenue, and the filing's arithmetic is unsentimental: a spending base built for a $18 billion revenue year is being right-sized for a far smaller one. The contrarian point is not that the platform fails — it is that the market keeps pricing the optionality while the company keeps pricing the cliff into its own expense decisions.
The skeptic's discipline: no price target, no forecast — just the disclosed lines. Every figure above is quoted from Moderna's primary SEC filings, surfaced via EdgarBeast as a filing-evidence index, with the FY2025 10-K on sec.gov as the record.